Angiotensin II type 1 receptor blocker attenuates myocardial remodelling and preserves diastolic function in diabetic heart

Hypertension Research

Volumn 30, Issue 5, 2007, Pages 439-449

  Tsutsui, Hiroyuki ^a   Matsushima, Shouji ^a,b   Kinugawa, Shintaro ^a   Ide, Tomomi ^b   Inoue, Naoki ^a   Ohta, Yukihiro ^a   Yokota, Takashi ^a   Hamaguchi, Sanae ^a   Sunagawa, Kenji ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Diabetes mellitus; Extracellular matrix; Oxidative stress; Remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; MATRIX METALLOPROTEINASE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLE; ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MORBIDITY; MORTALITY; MOUSE; MUSCLE RELAXATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RISK FACTOR; SYSTOLE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIASTOLE; ECHOCARDIOGRAPHY; FIBROBLASTS; HEART FAILURE, CONGESTIVE; HEART RATE; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED STRAINS; MYOBLASTS, CARDIAC; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34250739965     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.439     Document Type: Article

References (43)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287 2570-2581.
2. Mizushige K, Yao L, Noma T, et al: Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
3. Fiordaliso, F, Li B, Latini R, et al: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000; 80: 513-527.
4. Kim S, lwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and. renal diseases. Pharmacol Rev 2000; 52: 11-34.
5. Way KJ, Isshiki K, Suzuma K, et al: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-2718.
6. Matsushima S, Kinugawa S, Ide T, et al: Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006; 291: H2237-H2245.
7. Matsushima S, Ide T, Yamato M, et al: Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2006; 113: 1779-1786.
8. Knollmann BC, Blatt SA, Horton K, et al: Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem 2001; 276: 10039-10048.
9. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM: Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993; 72: 1245-1254.
10. Fiordaliso F, Leri A, Cesselti D, et al: Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001; 50: 2363-2375.
11. Young ME, McNulty P, Taegtmeyer H: Adaptation and maladaptation of the heaPt in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861-1870.
12. Shiomi T, Tsutsui H, Ikeuchi M, et al: Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial intarction. J Am Coll Cardiol 2003; 42 165-172.
13. Riva E, Andreoni G, Bianchi R, et al: Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res 1998; 37: 233-240.
14. Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S: Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest 1990; 86: 481-488.
15. Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905-1912.
16. Yamamoto K, Masuyama T, Sakata Y, et al: Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82.
17. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
18. Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A: Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a type II diabetic rat model. Diabetologia 2002; 45: 402-415.
19. Twigg SM, Cao Z, SV MC, et al: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 4907-4915.
20. Grotendorst GR, Okochi H, Hayashi N: A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469-480.
21. Gore-Hyer E, Shegogue D, Markiewicz M, et al: TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002; 283: F707-F716.
22. Liu BC, Chen Q, Luo DD, et al: Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67-73.
23. Yu J, Prado GN, Taylor L, et al: Global chimeric exchanges within the intracellular face of the bradykinin B2 receptor with corresponding angiotensin II type Ia receptor regions: Generation of fully functional hybrids showing characteristic signaling of the AT 1a receptor. J Cell Biochem 2002; 85: 809-819.
24. Iwanciw D, Rehm M, Porst M, Goppelt-Struebe M: Induction of connective tissue growth factor by angiotensin II: Integration of signaling pathways. Arterioscler Thromb Vasc Biol 2003; 23: 1782-1787.
25. Ricupero DA, Romero JR, Rishikof DC, Goldstein RH: Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 2000; 275: 12475-12480.
26. Williams B: Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001; 87: 10C-17C.
27. Hayashidani S, Tsutsui H, Ikeuchi M, et al: Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285: H1229-H1235.
28. Matsusaka H, Ide T, Matsushima S, et al: Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006; 47: 711-717.
29. Weber KT: Extracellular matrix remodeling inAheart failure: a role for de novo angiotensin II generation. Circulation 1997; 96 4065-4082.
30. Kakkar R, Kalra J, Mantha SV, Prasad K: Lipid peroxidation and activity of antioxidant enzymes in diabetic rats. Mol Cell Biochem 1995; 151: 113-119.
31. Kanazawa A, Nishio Y, Kashiwagi A, Inagaki H, Kikkawa R, Horiike K: Reduced activity of mtTFA decreases the transcription in mitochondria, isolated from diabetic rat heart. Am J Physiol Endocrinol Metab 2002; 282: E778-E785.
32. Fiordaliso F, Bianchi R, Staszewsky L, et al: Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004; 37: 959-968.
33. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
34. Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ: Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: The role of angiotensin II. Circ Res 2000; 86: 463-469.
35. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G: Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: Role of enhanced vascular superoxide production. Circulation 1999; 100: 292-298.
36. Okada K, Hirano T, Ran J, Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27: 293-299.
37. Investigators HOPEHS, Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
38. Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
39. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
40. Jessup M, Brozena, S: Heart failure. N Engl J Med 2003; 348: 2007-2018.
41. Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: E154-e235.
42. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362: 772-776.
43. Shiomi T, Tsutsui H, Hayashidani S, et al: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-3132.